Together, our data demonstrate that, whilst the BIM deletion is sufficient to confer resistance to GCs, the negative impact of polymorphic variants on single agent therapy can be overcome with multi-agent chemotherapy that kill cancer cells via divergent mechanisms. Here, BCL2L11 is linked to cancer.